Recall of Thymoglobuline 5 mg/ml Powder for Concentrate for Solution for Infusion

Sanofi-aventis, in consultation with the Health Sciences Authority (HSA) would like to inform you that Genzyme, a Sanofi Company, is initiating a voluntary recall of 2 lots of Thymoglobuline 5 mg/ml Powder for concentrate for solution for infusion. The lot numbers are C0074 and C0088. The affected lots of Thymoglobuline® are being recalled due to the potential risk for a stability failure prior to end of shelf life for aggregation. Healthcare professionals are advised to stop using the Thymoglobuline® from the affected lots and to refer to the letter for more details.

 
 
Healthcare professional, Therapeutic Products
Published:

Dear Healthcare Professional Letters

12 Dec 2019

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.hpp.moh.gov.sg/, and follow the procedures below to access the MOH Alert system.

Step 1: Scroll down to the bottom navigation panel of the HPP web page. Under the Healthcare Professionals section, expand the dropdown option for ‘Healthcare Professional Portal’ and select your profession. You will be redirected to the specific HPP web page to log in.

Step 2: Click on the Restricted Content icon on the left panel of the web page and log in via SingPass.

Step 3: Click on the MOH Alert icon under the ‘Applications’ section.

Step 4: Click on the Drug Alert tab to view the DHCPLs.